Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of lurbinectedin in advanced solid tumors
NL-OMON45543Phase 1Completed
- Sponsor
- PharmaMar
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lurbinectedin in Nonhematologic neoplasms, sponsored by PharmaMar. Primary endpoints: Mass balance and time course of excretion and Metabolite identification. Started May 2017; status: completed.
02
Drugs
lurbinectedin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON45543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45543.